Cyproheptadine and Chlorpromazine Effects on Spasticity
NCT ID: NCT01509885
Last Updated: 2012-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2010-07-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Complete Spinal Cord Injured Subjects
Patients with no motor scores in their legs and suffering a complete spinal cord injury.
No interventions assigned to this group
Incomplete Spinal Cord Injured Subjects
Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant women
* Elderly Patients and debilitated patients
* Alcoholic Patients
* Patients with:
* Known or suspected allergy to the medication or its ingredients
* Cardiovascular disease
* Hypotension
* Coronary artery disease
* Reduced liver or kidney function
* Comatose or depressed states due to CNS depressants
* Blood dyscrasias
* Bone marrow depression
* History of seizures
* Respiratory problems
* Hypocalcemia
* Monoamine oxidase inhibitor therapy
* Angle-closure glaucoma
* Stenosing peptic ulcer
* Symptomatic prostatic hypertrophy
* Bladder neck obstruction
* Pyloroduodenal obstruction
* History of bronchial asthma
* Increased intraocular pressure
* Hyperthyroidism
* Cardiovascular disease
* Hypertension
* Patients taking:
* Amphetamines
* Antihistamines-second generation
* Anticonvulsants
* Anticholinergics
* CNS depressants
* Antidepressants
* Hypotensive agents
* Levodopa
* Lithium
17 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monica A Gorassini, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico J, Harvey PJ, Li X, Harris RL, Ballou EW, Anelli R, Heckman CJ, Mashimo T, Vavrek R, Sanelli L, Gorassini MA, Bennett DJ, Fouad K. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med. 2010 Jun;16(6):694-700. doi: 10.1038/nm.2160. Epub 2010 May 30.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00020682
Identifier Type: -
Identifier Source: org_study_id